
-
抗体試薬
- フローサイトメトリー用試薬
-
ウェスタンブロッティング抗体試薬
- イムノアッセイ試薬
-
シングルセル試薬
- BD® AbSeq Assay
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Immune Profiler Protein Panel
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD® OMICS-One Protein Panels
-
細胞機能評価のための試薬
-
顕微鏡・イメージング用試薬
-
細胞調製・分離試薬
-
- BD® AbSeq Assay
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Immune Profiler Protein Panel
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD® OMICS-One Protein Panels
- Japan (Japanese)
-
Change country/language
Old Browser
Looks like you're visiting us from United States.
Would you like to stay on the current country site or be switched to your country?
BD FastImmune™ FITC Mouse Anti-Human TNF-α
クローン 6401.1111 (RUO (GMP))

.png)

.png)
Regulatory Statusの凡例
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation and Storage
The FITC and PE conjugates are each supplied in 1.0 mL of PBS. The APC conjugate is supplied in 0.5 mL of PBS. Buffered saline contains gelatin and 0.1% sodium azide. Please refer to the vial label for antibody concentration. The vial should be stored at 2° to 8°C. Conjugated forms should not be frozen and should be protected from prolonged exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.
Anti-Hu–TNF-α, clone 6401.1111, is derived from a fusion of Sp2/0 myeloma cells with splenocytes from BALB/c mice immunized with recombinant human TNF-α.
Anti-Human Tumor Necrosis Factor-α (Anti-Hu–TNF-α) recognizes a 26-kilodalton (kd) transmembrane protein.

Development References (19)
-
Aversa G, Punnonen J, de Vries JE. The 26-kD transmembrane form of tumor necrosis factor α on activated CD4+ T cell clones provides a co-stimulatory signal for human B cell activation. J Exp Med. 1993; 177:1575-1585. (Biology).
-
Beutler B, Cerami A. CachectMore than a tumor necrosis factor. N Eng J Med. 1987; 316:379-385. (Biology).
-
Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Ann Rev Biochem. 1988; 57:505-518. (Biology).
-
Cassatella MA, Meda L, Bonora S, et al. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993; 178:2207-2211. (Biology).
-
Decamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995; 154:882-892. (Biology).
-
Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996; 84(2):299-308. (Biology). View Reference
-
Jones EY, Stuart DI, Walker NPC. Structure of tumour necrosis factor. Nature. 1989; 338:225-228. (Biology).
-
Kinkhabwala M Sehajpal P, Skolnik E, et al. A novel addition to the T cell repertory, Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med. 1990; 171:941-946. (Biology).
-
Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988; 53(1):45-53. (Biology). View Reference
-
Martich GD, Danner RL, Ceska M, et al. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxThe effect of anti-inflammatory agents. J Exp Med. 1991; 173:1021-1024. (Biology).
-
Mestan J, Digel W, Mittnacht S, et al. Antiviral effects of tumour necrosis factor in vitro. Nature. 1986; 323:816-819. (Biology).
-
Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Eng J Med. 1988; 318:1481-1486. (Biology).
-
Old LJ. Tumor necrosis factor (TNF). Science. 1985; 230:630-632. (Biology).
-
Saklatvala J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Science. 1986; 322:547-549. (Biology).
-
Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994; 76(6):959-962. (Biology). View Reference
-
Sung SJ, Bjorndahl JM, Wang CY, et al. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med. 1988; 168:1539-1551. (Biology).
-
Sypek JP, Wyler DJ. Antileishmanial defense in macrophages triggered by tumor necrosis factor expressed on CD4+ T lymphocyte plasma membrane. J Exp Med. 1991; 174:755-759. (Biology).
-
Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986; 234:470-474. (Biology).
-
Wong GH, Goeddel D. Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature. 1986; 323:819-822. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Although not required, these products are manufactured in accordance with Good Manufacturing Practices.